Nymox Pharmaceutical Corporation (NYMX)
NYMXPrice: $0.2
Fair Value: 🔒
🔒score
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trial... more
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and developme... more
Description
Shares
| Market Cap | $18.24M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | BS | CEO | Paul Averback DABP, |
| IPO Date | 1997-11-26 | CAGR | — |
| Employees | 3 | Website | nymox.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
NYMX chart loading...
Fundamentals
Technicals
| Enterprise Value | $18.01M | P/E Ratio | -2.86 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | -1.41 |
| P/CF Ratio | -13.35 | P/FCF Ratio | -13.39 |
| EPS | $-0.07 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | — | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | 0.24% | ROA | -2.41% |
| ROCE | 0.21% | Current Ratio | 0.09 |
| Quick Ratio | 0.09 | Cash Ratio | 0.01 |
| Debt/Equity | — | Interest Coverage | -9.67 |
| Altman Z Score | -1079.06 | Piotroski Score | 3 |